|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Patel C, Ahmed A and Ellsworth P: Renal
cell carcinoma: a reappraisal. Urol Nurs. 32:182–190.
2012.PubMed/NCBI
|
|
3
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar
|
|
4
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang Z, Chu PG, Woda BA, et al: Analysis
of RNA-binding protein IMP3 to predict metastasis and prognosis of
renal-cell carcinoma: a retrospective study. Lancet Oncol.
7:556–564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suh JH, Oak T, Ro JY, Truong LD, Ayala AG
and Shen SS: Clinicopathologic features of renal cell carcinoma in
young adults: a comparison study with renal cell carcinoma in older
patients. Int J Clin Exp Pathol. 2:489–493. 2009.PubMed/NCBI
|
|
7
|
Lopez-Beltran A, Scarpelli M, Montironi R
and Kirkali Z: 2004 WHO classification of the renal tumors of the
adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheville JC, Lohse CM, Zincke H, Weaver AL
and Blute ML: Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma. Am J Surg Pathol.
27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi YD, Kim KS, Ryu S, et al: Claudin-7
is highly expressed in chromophobe renal cell carcinoma and renal
oncocytoma. J Korean Med Sci. 22:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fu L, Wang G, Shevchuk MM, Nanus DM and
Gudas LJ: Activation of HIF2α in kidney proximal tubule cells
causes abnormal glycogen deposition but not tumorigenesis. Cancer
Res. 73:2916–2925. 2013.
|
|
11
|
Metcalf JL, Bradshaw PS, Komosa M, Greer
SN, Stephen Meyn M and Ohh M: K63-ubiquitylation of VHL by SOCS1
mediates DNA double-strand break repair. Oncogene. 20:1055–1065.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang N, Wu P, Wu L, et al: The
differential expression of vascular endothelial growth inhibitor
isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal
cell carcinoma. Cancer Genomics Proteomics. 10:47–53. 2013.
|
|
13
|
Wood CG: Molecular markers of prognosis in
renal cell carcinoma: Insight into tumor biology helps define risk
and provides targets for therapy. J Surg Oncol. 94:264–265. 2006.
View Article : Google Scholar
|
|
14
|
Fritzsche FR, Riener MO, Dietel M, Moch H,
Jung K and Kristiansen G: GOLPH2 expression in renal cell cancer.
BMC Urol. 8:152008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsimafeyeu I, Demidov L, Stepanova E, Wynn
N and Ta H: Overexpression of fibroblast growth factor receptors
FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol.
45:190–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cairns P: Renal cell carcinoma. Cancer
Biomark. 9:461–473. 2010.
|
|
17
|
Lai Y, Yu Z, Wang Y and Ye J:
Identification of PCAG1 as a novel prostate cancer-associated gene.
Mol Med Rep. 7:755–760. 2013.PubMed/NCBI
|
|
18
|
Krizman DB, Wagner L, Lash A, Strausberg
RL and Emmert-Buck MR: The Cancer Genome Anatomy Project: EST
sequencing and the genetics of cancer progression. Neoplasia.
1:101–106. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun S, Du R, Gao J, et al: Expression and
clinical significance of Notch receptors in human renal cell
carcinoma. Pathology. 41:335–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maaser K, Daubler P, Barthel B, et al:
Oesophageal squamous cell neoplasia in head and neck cancer
patients: upregulation of COX-2 during carcinogenesis. Br J Cancer.
88:1217–1222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lam JS, Pantuck AJ, Belldegrun AS and
Figlin RA: Protein expression profiles in renal cell carcinoma:
staging, prognosis, and patient selection for clinical trials. Clin
Cancer Res. 13:703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chuang MJ, Sun KH, Tang SJ, et al:
Tumor-derived tumor necrosis factor-alpha promotes progression and
epithelial-mesenchymal transition in renal cell carcinoma cells.
Cancer Sci. 99:905–913. 2008. View Article : Google Scholar
|
|
24
|
Linehan WM, Lerman MI and Zbar B:
Identification of the von Hippel-Lindau (VHL) gene. Its role in
renal cancer. JAMA. 273:564–570. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schraml P, Struckmann K, Hatz F, et al:
VHL mutations and their correlation with tumour cell proliferation,
microvessel density, and patient prognosis in clear cell renal cell
carcinoma. J Pathol. 196:186–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bui MH, Seligson D, Han KR, et al:
Carbonic anhydrase IX is an independent predictor of survival in
advanced renal clear cell carcinoma: implications for prognosis and
therapy. Clin Cancer Res. 9:802–811. 2003.PubMed/NCBI
|
|
27
|
Stillebroer AB, Mulders PF, Boerman OC,
Oyen WJ and Oosterwijk E: Carbonic anhydrase IX in renal cell
carcinoma: implications for prognosis, diagnosis, and therapy. Eur
Urol. 58:75–83. 2010. View Article : Google Scholar
|
|
28
|
Di Cello F, Shin J, Harbom K and Brayton
C: Knockdown of HMGA1 inhibits human breast cancer cell growth and
metastasis in immunodeficient mice. Biochem Biophys Res Commun.
2013.PubMed/NCBI
|
|
29
|
Loyd CM, Diaconu D, Fu W, et al:
Transgenic overexpression of keratinocyte-specific VEGF and Ang1 in
combination promotes wound healing under nondiabetic but not
diabetic conditions. Int J Clin Exp Pathol. 5:1–11. 2012.
|
